On November 21st,
a relatively small biotech company named Gilead Sciences (GILD) made headline news in the pharmaceutical investment community when it acquired a little - known hepatitis C drug developer named Pharmasset Inc. (VRUS), for $ 10.8 billion, in an all - cash deal.